Linde heads into its third-quarter report with two stories that do not quite agree. Demand looks healthier than it has in some time, with a record backlog, a fresh $1 billion electronics win and volumes finally recovering in the Americas and Asia. Yet the company that built its reputation on steady margin expansion just posted its first year-over-year margin decline, and management responded by putting its US home care business, Lincare, under strategic review. The October 29 release, due before the open, is the first chance to see whether that margin dip was a blip or a trend.
Wall Street expects earnings of $4.52 a share on revenue of about $9.18 billion, which would mean growth of roughly 7.4% and 6.6%, respectively. That is solid but unspectacular, and a step down from the 10% EPS growth Linde delivered last quarter. Revenue is also forecast slightly below the second quarter's record $9.29 billion, so the Street is not counting on sequential top-line momentum. The Earnings Whisper of $4.53 sits a penny above consensus, too small to signal a meaningfully higher bar. Both figures fall in the upper half of management's guidance of $4.45 to $4.55. The full-year picture is more telling. Linde has raised the bottom of its 2026 range three times, from $17.40 to $17.60 to $17.70, but has held the top at $17.90. Consensus of $17.89 is essentially pinned to that ceiling, which means analysts already assume Linde delivers at the high end of its own outlook.
That makes margins the swing factor. Operating margin slipped to 29.5% last quarter, down 60 basis points from a year earlier, with Lincare responsible for roughly $40 million of quarterly drag from labor inflation and reimbursement pressure. Dilutive mix from equipment and hard goods sales added to the pressure. Management said plainly it was not satisfied. A stabilization near 30% or better, or any sign that the Lincare penalty is shrinking, would support the idea that the core gases business remains as profitable as ever. Another year-over-year decline would raise harder questions, particularly if the hit spreads beyond home care. Any concrete progress on the strategic review, whether a partial sale or full exit, could reshape the margin narrative overnight.
On the growth side, the backlog is the scoreboard. It jumped $1 billion to $8.1 billion last quarter, and management has promised it will still start with an eight at year-end despite roughly $1.3 billion of project startups. Holding that level would show new wins are replacing completed projects. Electronics, which accelerated to 18% growth from 10% in the prior quarter, needs to keep carrying the load, while the Americas manufacturing recovery and two straight quarters of 6% Asian volume growth face a test from Middle East disruption that has been weighing on industrial activity in India, Southeast Asia and Australia. Helium is a wild card working in Linde's favor: pricing is firm, new long-term contracts are signed, and none of that upside is baked into guidance, even though supply normalization has slipped into early 2027.
The mood has warmed considerably. Sentiment has climbed to 38% bullish from barely positive ahead of the last report, and the stock has gained 5.7% since then, beating the S&P 500 by 2.4 percentage points. Shares near $502 sit above the 200-day moving average and within 1% of the post-earnings high of $506.38, so the stock is testing a breakout, though it remains well below the prior quarter's peak near $548.
With consensus already parked at the top of the full-year range, a modest beat may not be enough. The narrative holds if Linde shows margins have bottomed while the backlog stays above $8 billion. Raising the $17.90 ceiling would be the clearest sign management now trusts the volume recovery it has been reluctant to forecast.